Garth Lees-Rolfe
Financieel Directeur/CFO bij INHIBIKASE THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Garth Lees-Rolfe is currently the Chief Financial Officer at Inhibikase Therapeutics, Inc. He previously worked as the Vice President-Finance at F-star Therapeutics, Inc. Mr. Lees-Rolfe completed his undergraduate degree at Queensland University of Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-04-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Garth Lees-Rolfe
| Bedrijven | Functie | Begin |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Financieel Directeur/CFO | 31-03-2024 |
Eerdere bekende functies van Garth Lees-Rolfe
| Bedrijven | Functie | Einde |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01-11-2022 |
Opleiding van Garth Lees-Rolfe
| Queensland University of Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
